15966 Rates of malignancies through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Autor:	Stephen J. Rozzo, Jeff Parno, Jennifer Clay Cather, Beatrice Nardone, Elizabeth N. Ergen, Alan M. Mendelsohn
Rok vydání:	2020
Předmět:	Clinical trial Oncology medicine.medical_specialty business.industry Internal medicine Phase (matter) Tildrakizumab medicine Dermatology business
Zdroj:	Journal of the American Academy of Dermatology. 83:AB165
ISSN:	0190-9622
DOI:	10.1016/j.jaad.2020.06.750
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4b7759d4bc06460d34fa7a07f3e47f55 https://doi.org/10.1016/j.jaad.2020.06.750 Zobrazit plný text záznamu Full Text from ScienceDirect